OPTI vs. SBTX, ONC, DEST, HEMO, OBI, NSCI, SNG, OBD, SAR, and BVX
Should you be buying OptiBiotix Health stock or one of its competitors? The main competitors of OptiBiotix Health include SkinBioTherapeutics (SBTX), Oncimmune (ONC), Destiny Pharma (DEST), Hemogenyx Pharmaceuticals (HEMO), Ondine Biomedical (OBI), NetScientific (NSCI), Synairgen (SNG), Oxford BioDynamics (OBD), Sareum (SAR), and BiVictriX Therapeutics (BVX). These companies are all part of the "biotechnology" industry.
OptiBiotix Health (LON:OPTI) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
OptiBiotix Health received 98 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 59.18% of users gave OptiBiotix Health an outperform vote.
OptiBiotix Health's return on equity of -85.52% beat SkinBioTherapeutics' return on equity.
SkinBioTherapeutics has lower revenue, but higher earnings than OptiBiotix Health. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than OptiBiotix Health, indicating that it is currently the more affordable of the two stocks.
5.9% of OptiBiotix Health shares are owned by institutional investors. Comparatively, 18.8% of SkinBioTherapeutics shares are owned by institutional investors. 12.5% of OptiBiotix Health shares are owned by company insiders. Comparatively, 19.8% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, OptiBiotix Health had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for OptiBiotix Health and 0 mentions for SkinBioTherapeutics. SkinBioTherapeutics' average media sentiment score of 0.00 beat OptiBiotix Health's score of -0.26 indicating that SkinBioTherapeutics is being referred to more favorably in the news media.
OptiBiotix Health has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.
Summary
SkinBioTherapeutics beats OptiBiotix Health on 8 of the 14 factors compared between the two stocks.
Get OptiBiotix Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiBiotix Health Competitors List
Related Companies and Tools
